Gilead Sciences, Inc. (GILD)
Gilead Sciences (GILD) Q2 Earnings and Revenues Beat Estimates
Gilead Sciences (GILD) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.61 per share. This compares to earnings of $1.34 per share a year ago.
Gilead Eyes A Breakout After Second-Quarter Sales, Earnings Beat
Gilead stock is nearing a breakout after the company reported better-than-expected second-quarter sales and profit.
Gilead quarterly profit beats Street estimates, revenue up 5%
Gilead Sciences on Thursday reported second-quarter profit that handily beat Wall Street estimates, driven by lower operating expenses and higher product sales, and the drugmaker raised its outlook for full-year earnings.
Gilead's New Anti-Obesity Drug: The Real Reason Behind The 25% Stock Surge?
After a disastrous performance in the first half of 2024, Gilead Sciences stock has rebounded strongly since mid-June. With Gilead Sciences due to report its Q2 results on Thursday, it's a good time to assess what we can expect and whether the rebound was justified. I will specifically discuss Gilead's novel GLP-1 receptor agonist, GS-4571, and other news that has emerged recently.
Countdown to Gilead (GILD) Q2 Earnings: Wall Street Forecasts for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Should You Buy, Sell or Hold Gilead Sciences (GILD) Before Q2 Earnings?
While Gilead (GILD) has been under pressure year to date due to pipeline setbacks, holding on to this biotech giant should be prudent at current levels.
Gilead Sciences (GILD) Advances While Market Declines: Some Information for Investors
Gilead Sciences (GILD) closed the most recent trading day at $76.49, moving +0.57% from the previous trading session.
Gilead Sciences (GILD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
A Look At Gilead Sciences After Its Recent Weakness
Gilead Sciences has dropped 15% YTD, impacted by disappointing trial results from Trodelvy after acquiring Immunomedics for over $20 billion. Despite challenges, the company had a financially strong 1Q 2024, with growth in non-Veklury product sales and a strong HIV business. Gilead Sciences has an impressive R&D arm and strong financial performance, with a focus on building a balanced portfolio for long-term shareholder returns.
3 Stocks That Can Help You to Get Richer in 2024 and Beyond
Pfizer is busy growing income streams to replace its big COVID-related revenue from years past. Paycom is profitably helping companies help themselves with self-service software.
